Campath-1H (Alemtuzumab) as an Induction Agent for the Prevention of Graft Rejection and Preservation of Renal Function in Kidney Transplant Patients: Philippine 3-Year Follow-up

Three years posttransplantation, patients given Campath induction with CsA monotherapy showed a greater incidence of ARE, although renal function remained comparable to CsA-azathioprine-prednisone therapy. AREs were easily reversed with steriods. Infections were minor.